European Primary Care Cardiovascular Society

Surprising results observed with head-to-head comparison of P2Y12-inhibitors in ACS

3' education - Sep. 16, 2019 - Paris, France - Prof. Stefanie Schüpke

Reduced blood pressure and incidence of hypertension with community-wide salt restriction

3' education - Sep. 16, 2019 - Paris, France - Prof. Jaime Miranda

Reduced CV risk with an intervention targeting identified barriers to care

3' education - Sep. 16, 2019 - Paris, France - Prof. J-D Schwalm

The impact of preventive measures stressed by large community-based studies

3' education - Sep. 16, 2019 - Paris, France - Prof. Salim Yusuf

SGLT2 inhibitor largely reduced CV risk in HFrEF with or without diabetes

3' education - Sep. 16, 2019 - Paris, France - Prof. John McMurray

Lower LDL-c targets in the 2019 ESC/EAS Dyslipidaemia Guidelines: this is why

5' education - Sep. 9, 2019 - Prof. François Mach

Moving from ignorance on the complexity of HDL to novel therapeutic opportunities

3' education - June 3, 2019 - EAS Maastricht, 2019 - John Chapman, PhD

Efforts to move universal cholesterol screening before the age of 20 forward

3' education - May 29, 2019 - Maastricht, The Netherlands - Professor Kausik Ray, MD

U-Prevent helps to assess individual CV risk and treatment effect

10' education - July 3, 2019 - Jannick Dorresteijn, MD, PhD

The cardiovascular challenge for primary care in diabetes

10' education - Apr. 11, 2019 - EuroPrevent 2019 - Prof. Richard Hobbs, MD

T2DM & CV outcomes: More than glucose management? - Lessons from GLP-1RA trials

10' education - Apr. 11, 2019 - EuroPrevent 2019 - Stephan Jacob, MD

Targeting CVD in diabetes: Novel strategies to tackle the risk

10' education - Apr. 11, 2019 - EuroPrevent 2019 - John Deanfield, MD

Lowering remnants becomes more important, also in light of the obesity epidemic

3' education - June 19, 2019 - EAS 2019 - Prof. Børge Nordestgaard
EPCCS Annual CV Summit

New diagnostic algorithm and therapeutic options in HF management

5' education - Mar. 22, 2019 - Lisbon, Portugal - Peter van der Meer & Monika Hollander
EPCCS Annual CV Summit

Update on managing CV risk in diabetes: what's the evidence?

5' education - Mar. 22, 2019 - Lisbon, Portugal - Kamlesh Khunti & Richard Hobbs
EPCCS Annual CV Summit

Stroke prevention in atrial fibrillation

5' education - Mar. 21, 2019 - Lisbon, Portugal - Michaela Machácová & Richard Hobbs
EPCCS Annual CV Summit

Recent updates to the international Hypertension Guidelines - where do they vary and what should we agree in primary care?

5' education - Mar. 21, 2019 - Lisbon, Portugal - Richard McManus & Richard Hobbs
EPCCS Annual CV Summit

Multimorbidity, CV disease and polypharmacy

10' education - Mar. 21, 2019 - Lisbon, Portugal - Dr. David Silvério Rodrigues

Lifestyle improvement forms the basis of comprehensive ACC/AHA guideline for primary prevention

3' education - Mar. 20, 2019 - New Orleans, LA, USA - Dr. Amit Khera

Implementation of advice facilitated by new overarching recommendations in ACC/AHA primary prevention guideline

3' education - Mar. 20, 2019 - New Orleans, LA, USA - Donna Arnett, MD

Early combination therapy gives better glucose control in newly diagnosed T2DM

News - Sep. 18, 2019

EASD 2019 The VERIFY trial demonstrated that early combination therapy using vildagliptin and metformin was superior to a sequential approach involving later intensification in new T2DM

In normal BMI post-menopausal women, trunk fat was associated with higher and leg fat with lower CVD risk

Literature - Sep. 16, 2019 - Chen G-C et al., - Eur Heart J. 2019

Data of US postmenopausal women with normal BMI show that trunk fat and higher leg fat have opposing associations with CVD risk, while total body fat was not significantly related to CVD risk.

Surprising results observed with head-to-head comparison of P2Y12-inhibitors in ACS

3' education - Sep. 16, 2019 - Paris, France - Prof. Stefanie Schüpke
Contrary to the hypothesis that ticagrelor would be superior, a prasugrel-based strategy reduces ischemic endpoints, without an increased bleeding risk.

ESC 2019 Contrary to the hypothesis that ticagrelor would be superior, a prasugrel-based strategy reduced ischemic endpoints as compared with ticagrelor, without an increased bleeding risk.

Reduced blood pressure and incidence of hypertension with community-wide salt restriction

3' education - Sep. 16, 2019 - Paris, France - Prof. Jaime Miranda
A stepped-wedge cluster randomized controlled trial showed that a salt-substitution strategy in 6 villages in Peru lowered blood pressure and reduced incidence of hypertension by half.

ESC 2019 A stepped-wedge cluster randomized controlled trial showed that a salt-substitution strategy in 6 villages in Peru lowered blood pressure and reduced incidence of hypertension by half.

Reduced CV risk with an intervention targeting identified barriers to care

3' education - Sep. 16, 2019 - Paris, France - Prof. J-D Schwalm
In community-based studies in Colombia and Malaysia, HOPE-4 achieved reduced CV risk, better treatment adherence and healthier behavior with an intervention that targeted previously identified barriers to care.

ESC 2019 In community-based studies in Colombia and Malaysia, HOPE-4 achieved reduced CV risk, better treatment adherence and healthier behavior with an intervention that targeted previously identified barriers to care.

The impact of preventive measures stressed by large community-based studies

3' education - Sep. 16, 2019 - Paris, France - Prof. Salim Yusuf
Data of the HOPE-4 and PURE studies confirm the impact of reducing common risk factors, and point at less acknowledged risk factors, such as home air pollution and educational level.

ESC 2019 Data of the HOPE-4 and PURE studies confirm the impact of reducing common risk factors, and point at less acknowledged risk factors, such as home air pollution and educational level.

SGLT2 inhibitor largely reduced CV risk in HFrEF with or without diabetes

3' education - Sep. 16, 2019 - Paris, France - Prof. John McMurray
DAPA-HF evaluated dapagliflozin in addition to standard therapy in HFrEF patients with or without diabetes, and showed a risk reduction of 26% in worsening of HF and CV death.

ESC 2019 DAPA-HF evaluated dapagliflozin in addition to standard therapy in HFrEF patients with or without diabetes, and showed a risk reduction of 26% in worsening of HF and CV death.

CRP levels in patients with stable CVD related to recurrent CV events, and also to cancer

Literature - Sep. 12, 2019 - Van ’t Klooster CC et al. - Eur Heart J 2019

Data of a prospective cohort suggest that chronic systemic low-grade inflammation, as measured by CRP, plays a role in development of cancer, particularly of the lung, in those with stable CVD.

Lower LDL-c targets in the 2019 ESC/EAS Dyslipidaemia Guidelines: this is why

5' education - Sep. 9, 2019 - Prof. François Mach
Prof. François Mach was co-chair of the Task Force that composed the new ESC/EAS Dyslipidaemia Guidelines. He lists some of the changes compared to the previous version and explains why he supports the changes.

ESC 2019 Prof. François Mach was co-chair of the Task Force that composed the new ESC/EAS Dyslipidaemia Guidelines. He lists some of the changes compared to the previous version and explains why he supports the changes.

Global FH registry data reveal that FH patients are insufficiently treated

News - Sep. 9, 2019

ESC 2019 The first data in the FH Studies Collaboration registry show that among 42,000 adults with heterozygous FH, about half of patients received a statin and the majority was not at LDL-c goal.

Lifelong modestly lower LDL-c and SBP greatly reduces CV risk

News - Sep. 4, 2019
Using genetic scores to assess lifelong exposure to LDL-c and SBP levels, suggests that relatively small differences in this exposure associated large proportional risk reductions.

ESC 2019 Using genetic scores to assess lifelong exposure to LDL-c and SBP levels, suggests that relatively small differences in this exposure associated large proportional risk reductions.

New ESC/EAS dyslipidaemia guidelines: “lower is better” for LDL-c

News - Sep. 4, 2019
The guidelines emphasize that the absolute LDL-C reduction drives the clinical benefit. Evidence suggests a benefit of treating earlier, which may mean less intensive therapy in the longer-term.

ESC 2019 The guidelines emphasize that the absolute LDL-C reduction drives the clinical benefit. Evidence suggests a benefit of treating earlier, which may mean less intensive therapy in the longer-term.